



Cochrane
Library

Cochrane Database of Systematic Reviews

Interventions to reduce tobacco use in people experiencing homelessness (Protocol)

Vijayaraghavan M, Elser H, Apollonio D

Vijayaraghavan M, Elser H, Apollonio D.

Interventions to reduce tobacco use in people experiencing homelessness.

Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013413.

DOI: 10.1002/14651858.CD013413.

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
BACKGROUND	1
OBJECTIVES	3
METHODS	3
ACKNOWLEDGEMENTS	6
REFERENCES	6
APPENDICES	8
CONTRIBUTIONS OF AUTHORS	9
DECLARATIONS OF INTEREST	9
SOURCES OF SUPPORT	9

Interventions to reduce tobacco use in people experiencing homelessness

Maya Vijayaraghavan¹, Holly Elser², Dorie Apollonio³

¹Division of General Internal Medicine, University of California, San Francisco, San Francisco, California, USA. ²Epidemiology, University of California, Berkeley, Berkeley, California, USA. ³Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA

Contact address: Maya Vijayaraghavan, Division of General Internal Medicine, University of California, San Francisco, San Francisco, California, USA. Maya.vijayaraghavan@ucsf.edu.

Editorial group: Cochrane Tobacco Addiction Group.

Publication status and date: New, published in Issue 9, 2019.

Citation: Vijayaraghavan M, Elser H, Apollonio D. Interventions to reduce tobacco use in people experiencing homelessness. *Cochrane Database of Systematic Reviews* 2019, Issue 9. Art. No.: CD013413. DOI: 10.1002/14651858.CD013413.

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess whether interventions designed to improve access to smoking cessation interventions for adults experiencing homelessness and interventions designed to help adults experiencing homelessness to quit smoking lead to increased engagement and tobacco abstinence. To also assess whether smoking cessation interventions for adults experiencing homelessness affect substance use and mental health.

BACKGROUND

Description of the condition

Tobacco use is disproportionately concentrated among low-income populations, with rates exceeding that of the general population at least two-fold (Jamal 2015). Among low-income populations, such as people experiencing homelessness, estimated smoking prevalence ranges between 60% and 80% (Baggett 2013). Individuals with severe mental health disorders and/or substance use disorders who belong to racial/ethnic minority groups, who are older, or who self-identify as a gender and sexual minority are disproportionately represented in populations experiencing homelessness (Culhane 2013; Fazel 2014). The prevalence of mental health and substance use disorders is high among people experiencing homelessness. A systematic review concluded that the

most common mental health disorders among this population were drug (range 5% to 54%) and alcohol dependence (range 8% to 58%), and that the prevalence of psychosis (range 3% to 42%) was as high as that of depression (range 0% to 59%) (Fazel 2008). These populations carry a high burden of tobacco use and tobacco-related morbidity and mortality (Schroeder 2009). Persons experiencing homelessness are three to five times more likely to die prematurely than those who are not homeless (Baggett 2015; Hwang 2009), and tobacco-related chronic diseases are the leading causes of morbidity and mortality among those aged 45 and older (Baggett 2013b). Among younger homeless-experienced adults (< 45 years), the incidence of tobacco-related chronic diseases is three times higher than the incidence in age-matched non-homeless adults (Baggett 2013b).

Persons experiencing homelessness have distinctive tobacco use behaviors associated with low income, substance use comorbidities,

and housing instability that affect their likelihood of successfully quitting. Epidemiological studies of tobacco use among this population have shown that most adults experiencing homelessness initiate smoking before the age of 16 (Arnsten 2004). Average daily cigarette consumption is between 10 and 13 cigarettes per day, and more than one-third smoke their first cigarette within 30 minutes of waking (Okuyemi 2006; Vijayaraghavan 2015; Vijayaraghavan 2017). People experiencing homelessness have high rates of concurrent use of alternative tobacco products such as little cigars, smokeless tobacco, and e-cigarettes (Baggett 2016; Neisler 2018). They also engage in high-risk smoking practices including exposure compensation when reducing cigarettes smoked per day and smoking cigarette butts (Garner 2013; Vijayaraghavan 2018). Smoking norms include sharing or “bumming” cigarettes, and these practices may reduce the effects of policy interventions such as increased taxes (Garner 2013; Vijayaraghavan 2018). Individuals experiencing homelessness face significant barriers to cessation, including disproportionately high rates of post-traumatic stress disorder (PTSD), which can lead to positive associations with smoking (Baggett 2016a). Smoking cessation is challenging for people who have to navigate the stressors of homelessness (Baggett 2018; Chen 2016), high levels of nicotine dependence, and limited access to smoking cessation treatment and smoke-free living environments (Vijayaraghavan 2016; Vijayaraghavan 2016b). Integrating tobacco dependence treatment into existing services for homeless-experienced adults remains challenging (Vijayaraghavan 2016b). Staff members may not support quit attempts (Apollonio 2005; Garner 2013), and homeless-experienced adults do not have consistent access to services or information technologies used to improve access to cessation interventions (McInnes 2013). Despite these challenges, over 40% of adults experiencing homelessness report making a quit attempt in the past year (Baggett 2013c; Connor 2002). A majority relapse to smoking, with estimates of the quit ratio (i.e. the ratio of former-to-ever smokers) between 9% and 13% compared to 50% in the general population (Baggett 2013c; Vijayaraghavan 2016). Homeless populations have been historically neglected in population-wide tobacco control efforts; however, there has been increasing interest in studying the correlates of tobacco use and cessation behaviors for these populations and in discovering how these individuals may differ from the general population (Goldade 2011; Okuyemi 2013). Typically high levels of nicotine dependence among adults experiencing homelessness are associated with low likelihood of quitting (Vijayaraghavan 2014). Proximity to a shelter during the week after a quit attempt has been associated with higher risk of relapse, thought to occur because of increased exposure to environmental cues to smoking (Businelle 2014; Reitzel 2011). In contrast, staying in a shelter, as opposed to on the street, has been associated with quitting smoking (Vijayaraghavan 2016), possibly due to exposure to shelter-based smoke-free policies. Studies have shown that engaging in smoking cessation does not adversely affect substance use behaviors (Apollonio 2016), and has in-

creased the number of days abstinent from alcohol (Reitzel 2014). More recent research efforts such as have focused on designing interventions to reduce smoking initiation among youth experiencing homelessness (Shadel 2014), and to improve quit rates among adults experiencing homelessness (Baggett 2017; Carpenter 2015; Ojo-Fati 2015; Okuyemi 2006b; Okuyemi 2013; Rash 2018).

Description of the intervention

Interventions designed to support people to stop smoking can work to motivate people to attempt to stop smoking (“cessation induction”), or to support people who have already decided to stop to achieve abstinence (“aid to cessation”). In this review, we will include both types of interventions. Many people who are homeless face barriers to using regular services, such as healthcare services, through which cessation support is available. The availability of support to assist a quit attempt can itself create motivation to quit (Aveyard 2012). Thus one possible intervention to support people experiencing homelessness is to provide bespoke cessation services that can operate both to make quitting seem more desirable and to provide treatment for those who are attempting to stop smoking. The combination of behavioral counseling and pharmacotherapy (nicotine replacement therapy [NRT], bupropion, or varenicline) is the gold standard for individually tailored smoking cessation treatment in the general population (Stead 2016). However, a vast majority of quit attempts made by people experiencing homelessness are unassisted (Vijayaraghavan 2016). Preference for cessation aids may vary by cigarette consumption, with light smokers (0 to 10 cigarettes per day) preferring counseling over medication, in contrast to moderate/heavy smokers (> 10 cigarettes per day) (Nguyen 2015).

How the intervention might work

Cessation induction interventions directed at smokers who are not ready to quit rely on pharmacological, behavioral, or combination interventions to increase motivation and intention to quit, with an eventual goal of abstinence. Interventions may include nicotine therapy sampling to induce practice quit attempts, as described in Carpenter 2011, or motivational interviewing to induce cessation-related behaviors among smokers who are not motivated to quit, as examined in Catley 2016.

Tobacco dependence treatment can provide motivation and support for change through pharmacotherapy (Cahill 2013), counseling (Lancaster 2017), financial incentives (Notley 2019), or a combination of these (Stead 2016). Pharmacotherapy can reduce the urge to smoke and can decrease nicotine withdrawal symptoms via NRT, varenicline, or bupropion (Cahill 2013); counseling can provide support and motivation to make and continue with quit attempts (Lancaster 2017). For individuals with severe tobacco dependence, such as people experiencing homelessness,

multi-component interventions that include behavioral counseling, combination pharmacotherapy, and other adjunctive methods such as financial incentives - as discussed in [Businelle 2014b](#), [Baggett 2017](#), and [Rash 2018](#) - or mobile support - as offered in [Carpenter 2015](#) - may be beneficial. However, as many quit attempts are unassisted, more may need to be done to remove barriers and facilitate access to cessation support for smokers who are homeless.

Why it is important to do this review

People experiencing homelessness have unique tobacco use characteristics, including higher likelihood of irregular smoking patterns, reduced exposure to clean indoor air policies, and reliance on “used” cigarettes ([Baggett 2016](#); [Garner 2013](#); [Vijayaraghavan 2018](#)). They receive limited support for cessation from service providers ([Apollonio 2005](#); [Garner 2013](#)). Many countries have identified homeless-experienced adults as a high-risk group in need of targeted interventions ([Fazel 2014](#)). Tobacco use is the single most preventable cause of mortality among adults experiencing homelessness ([Baggett 2015](#)). Past efforts to promote tobacco cessation among this population have yielded mixed results that make it difficult to assess which types of tobacco dependence treatments promote abstinence. Our findings will synthesize evidence to date and will identify interventions that increase quit attempts and abstinence, as well as improve access to treatment, for this vulnerable population. We will also explore whether cessation interventions affect mental health or substance use outcomes among this population.

OBJECTIVES

To assess whether interventions designed to improve access to smoking cessation interventions for adults experiencing homelessness and interventions designed to help adults experiencing homelessness to quit smoking lead to increased engagement and tobacco abstinence. To also assess whether smoking cessation interventions for adults experiencing homelessness affect substance use and mental health.

METHODS

Criteria for considering studies for this review

Types of studies

We will include randomized controlled trials (RCTs) and cluster RCTs, with no exclusions based on language of publication or publication status.

Types of participants

Participants will include homeless and unstably housed adults (> 18 years of age). This will be defined by criteria specified by individual studies; however we envisage that participants will meet one or more of the following criteria for homelessness ([ANHD 2018](#); [Council to Homeless Persons 2018](#); [Fazel 2014](#)).

1. Individuals and families who do not have a fixed, regular, and adequate night-time residence, including individuals who live in emergency shelters for homeless individuals and families, and those who live in places not meant for human habitation.
2. Individuals and families who will imminently lose their main night-time residence.
3. Unaccompanied young adults and families with children and young people who meet other definitions of homelessness.
4. Individuals and families who are fleeing or attempting to flee domestic violence, dating violence, sexual assault, stalking, or other dangerous or life-threatening conditions that relate to violence against an individual or family member.
5. Individuals and families who live in transitional shelters or housing programs.
6. Individuals and families who are temporarily living with family or friends.
7. Individuals and families who are living in overcrowded conditions.

Participants must also be tobacco users who may or may not be motivated to quit.

Types of interventions

We will include in our review any interventions that:

1. focus on increasing motivation to quit, building capacity (e.g. providing education or training to provide cessation support to staff working with people who are homeless), or improving access to tobacco cessation services in clinical and non-clinical settings for homeless adults;
2. aim to help people making a quit attempt to achieve abstinence, including but not limited to behavioral support, tobacco cessation pharmacotherapies, contingency management, and app-based interventions; or
3. focus on transitions to long-term nicotine use that do not involve combustible tobacco.

Control groups may receive no intervention or ‘usual care’, as defined by individual studies.

Types of outcome measures

Primary outcomes

1. Tobacco abstinence (given the paucity of data on long-term cessation outcomes among people experiencing homelessness, we will also assess short-term cessation outcomes), assessed at three time points

- i) Short-term abstinence: < three months after quit day
- ii) Medium-term abstinence: \geq three months and < six months after quit day
- iii) Long-term abstinence: \geq six months after quit day

We will conduct separate analyses for each time point. We will use the strictest definition of abstinence used by the study, with preference for continuous or prolonged (allowing a grace period for slips) abstinence over point prevalence abstinence. When possible, we will extract biochemically verified rates (e.g. breath carbon monoxide, urinary/saliva cotinine) over self-report. We will assess abstinence on an intention-to-treat basis, using the number of people randomized as the denominator.

Secondary outcomes

1. Number of participants receiving treatment
2. Number of people making at least one quit attempt as defined by included studies
3. Abstinence from alcohol and other drugs as defined by self-reported drug use or through biochemical validation (or both), at the longest follow-up period reported in the study
4. Point prevalence or continuous estimates (e.g. questionnaire scores) for mental illnesses (including major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, schizophrenia, and bipolar disorder) as defined by previously validated survey instruments or physician diagnosis

Search methods for identification of studies

Electronic searches

We will search the Cochrane Tobacco Addiction Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), and MEDLINE. The MEDLINE search strategy is provided in [Appendix 1](#). The Specialized Register includes reports of tobacco-related trials identified through research databases, including MEDLINE, Embase, and PsycINFO, as well as via trial registries and handsearching of journals and conference abstracts. For a detailed account of searches carried out to populate the Register, see the [Cochrane Tobacco Addiction Group's website](#).

Searching other resources

We will search grey literature, including conference abstracts from the Society for Research on Nicotine and Tobacco. We will contact investigators in the field about potentially unpublished studies. We will additionally search for registered unpublished trials

through the National Institutes of Health clinical trials registry (www.clinicaltrials.gov) and the World Health Organization International Clinical Trials Registry Platform Search Portal (<http://apps.who.int/trialsearch/>).

Data collection and analysis

Selection of studies

We will merge search results using reference management software and will remove duplicate records. Two independent review authors (MV and HS) will examine the titles and abstracts to identify relevant articles and will subsequently retrieve and examine the full-text articles to assess adherence with the eligibility criteria. A third review author (DA) will independently assess whether the full-text articles meet eligibility criteria. We will exclude all studies that do not meet inclusion criteria in terms of study design, population, or interventions. We will resolve disagreements by discussion, and when necessary, the third review author will arbitrate the case.

Data extraction and management

Two review authors (MV and HS) will independently extract data in duplicate. We will contact study authors to obtain missing outcome data. Once outcome data have been extracted, one of the review authors (MV) will enter them into Review Manager 5.3, and another (HS) will check them ([Higgins 2011](#)). All review authors (MV, HS, and DA) will extract information from each study for risk of bias assessments.

We will extract the following information from study reports using a template developed by DA and modified by MV.

1. Source, including study ID, report ID, reviewer ID, citation, contact details, and country.
2. Methods, including study design, study objectives, study site, study duration, blinding, and sequence generation.
3. Participant characteristics, including total number enrolled and number in each group, setting, eligibility criteria, age, sex, race/ethnicity, sociodemographics, tobacco use (type, dependence level, amount used), mental illness, substance use, other comorbidities, and current residence (unsheltered, sheltered, single room occupancy hotel or temporary residence, or supportive housing).
4. Interventions, including total number of intervention groups and comparisons of interest, specific intervention, intervention details, and integrity of the intervention.
5. Outcomes, including definition, unit of measurement, and time points collected and reported.
6. Results, including participants lost to follow-up, summary data for each group, and subgroup analyses.

7. Miscellaneous items, including study author conflicts of interest, funding sources, and correspondence with study authors.

Assessment of risk of bias in included studies

Two review authors will assess the risk of bias for each included study, as outlined in the *Cochrane Handbook for Systematic Reviews of Interventions*, Chapter 8 (Higgins 2011). Using a risk of bias table, we will categorize risk of bias as “low risk,” “high risk,” or “unclear risk” for each domain, with the last category indicating insufficient information to judge risk of bias. We will assess the following domains: selection bias (including sequence generation and allocation concealment), blinding (performance bias and detection bias), attrition bias (incomplete outcome data), and any other bias. According to guidance from the Cochrane Tobacco Addiction Group, we will assess performance bias only for studies of pharmacotherapies, as it is impossible to blind behavioral interventions.

Measures of treatment effect

When possible, we will report a risk ratio (RR) and 95% confidence intervals (CIs) for the primary outcome (i.e. abstinence) for each included study. The risk ratio is defined as (number of participants in the intervention group who achieve abstinence/total number of people randomized to the intervention group)/(number of participants in the control group who achieve abstinence/total number of people randomized to the control group). We will use an intention-to-treat analysis, in which participants are analyzed based on the intervention to which they were randomized, irrespective of the intervention they actually received. For dichotomous secondary outcomes, such as number of people making a quit attempt and abstinence from substance use, we will calculate an RR with 95% CI for each study. For any continuous measures of our mental illness secondary outcome, we will calculate the mean difference (MD) or the standardized mean difference (SMD), as appropriate for each study.

Unit of analysis issues

The unit of analysis will be the individual. For cluster-randomized trials, we will assess whether study authors have adjusted for this clustering, and whether this had an impact on the overall result. When clustering appears to have had little impact on the results, we will use unadjusted quit rate data; however when clustering does appear to have an impact on results, we will adjust for this using the intraclass correlation (ICC).

Dealing with missing data

When outcome data are missing, we will attempt to contact the study authors to request missing data. For all outcomes apart from

mental health, we will assume that participants who are lost to follow-up are continuing smokers, are still using other substances, did not make a quit attempt, or did not receive treatment. We will report deaths separately and will not include participants who have died during the analysis. For the mental health outcome, we will conduct a complete case analysis.

Assessment of heterogeneity

We will classify heterogeneity as clinical, methodological, or statistical (Higgins 2011). We will not attempt a meta-analysis if we observe significant clinical or methodological heterogeneity between studies; we will instead report results in a narrative summary. If we feel it is appropriate to carry out meta-analyses, we will assess statistical heterogeneity using the I^2 statistic, which represents the percentage of the effect that is attributable to heterogeneity versus chance alone (Chapter 9; Higgins 2011). We will consider an I^2 value greater than 50% as evidence of substantial heterogeneity.

Assessment of reporting biases

We will assess several forms of reporting bias including outcome reporting bias (selective reporting of outcomes), location bias (publication of research in journals that may have different levels of access such as open access publication), and publication bias (publication or non-publication of studies depending on the direction of outcome effects), and we will discuss these in our review. We will assess whether abstinence from tobacco, our primary outcome, was reported in all included studies, and will report which studies included this outcome and which did not. If we include more than 10 studies in any analyses, we will generate a funnel plot to help us assess whether there could be publication bias.

Data synthesis

When meta-analysis is appropriate, we will use the Mantel-Haenszel random-effects method to calculate pooled, summary, weighted risk ratios (95% CIs), or inverse-variance random-effects methods to calculate pooled, summary, weighted MDs (95% CIs) or SMDs (95% CIs). We will pool separately studies testing interventions that aim to improve access to smoking cessation interventions and studies that are simply testing the effectiveness of smoking cessation interventions among people experiencing homelessness. Should meta-analyses not be possible, we will provide a narrative assessment of the evidence.

Subgroup analysis and investigation of heterogeneity

When possible, we will conduct subgroup analyses to examine whether outcomes differ based on:

1. intensity of treatment (e.g. number of counselling sessions);
2. participants' residential history (sheltered vs unsheltered);
3. participants' substance use history;

4. participants' diagnosis of mental health disorder; and
5. participants' use of non-cigarette tobacco and nicotine products.

Sensitivity analysis

We will conduct sensitivity analyses by excluding studies with high risk of bias (judged to be at high risk for one or more of the domains assessed).

Summary of findings

We will produce a "Summary of findings" table (Higgins 2011), presenting the primary outcome (tobacco use abstinence at all time points), absolute and relative magnitude of effects, numbers of par-

ticipants, and numbers of studies contributing to these outcomes. Two independent review authors will also carry out GRADE assessments of the certainty of evidence. Using GRADE criteria (study limitations, consistency of effect, imprecision, indirectness, and publication bias), we will grade the quality of evidence as very low, low, moderate, or high, and will provide footnotes to explain reasons for downgrading of evidence.

ACKNOWLEDGEMENTS

The review authors would like to thank Drs. Nicola Lindson, Paul Aveyard, and Jonathan Livingstone-Banks for their thoughtful review of draft versions of the protocol.

REFERENCES

Additional references

ANHD 2018

Association for Neighborhood and Housing Development. Growing Overcrowding, Growing Risk of Homelessness Shown in New Affordable Housing Neighborhood Risk Analysis. 2018. <https://anhd.org/press-release/growing-overcrowding-growing-risk-homelessness-shown-new-affordable-housing> (accessed 31 July 2019).

Apollonio 2005

Apollonio DE, Malone RE. Marketing to the marginalised: tobacco industry targeting of the homeless and mentally ill. *Tobacco Control* 2005;**14**(6):409–15. [PUBMED: PMC1748120]

Apollonio 2016

Apollonio DE, Philipps R, Bero LA. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. *Cochrane Database of Systematic Reviews* 2016, Issue 11. DOI: 10.1002/14651858.CD010274.pub2

Arnsten 2004

Arnsten JH, Reid K, Bierer M, Rigotti N. Smoking behavior and interest in quitting among homeless adults. *Addictive Behaviors* 2004;**29**(6):1155–61.

Aveyard 2012

Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. *Addiction* 2012;**107**(6):1066–73. DOI: 10.1111/j.1360-0443.2011.03770.x

Baggett 2013

Baggett TP, Tobey ML, Rigotti NA. Tobacco use among homeless people - addressing the neglected addiction. *New England Journal of Medicine* 2013;**369**(3):201–4. [PUBMED: PMID: 23863048]

Baggett 2013b

Baggett TP, Hwang SW, O'Connell JJ, Porneala BC, Stringfellow EJ, Orav EJ, et al. Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. *JAMA Internal Medicine* 2013;**173**(3):189–95.

Baggett 2013c

Baggett TP, Lebrun-Harris LA, Rigotti NA. Homelessness, cigarette smoking and desire to quit: results from a US national study. *Addiction* 2013;**108**(11):2009–18. [PUBMED: PMID: 23834157]

Baggett 2015

Baggett TP, Chang Y, Singer DE, Porneala BC, Gaeta JM, O'Connell JJ, et al. Tobacco-, alcohol-, and drug-attributable deaths and their contribution to mortality disparities in a cohort of homeless adults in Boston. *American Journal of Public Health* 2015;**105**(6):1189–97. [PUBMED: PMID: 25521869]

Baggett 2016

Baggett TP, Campbell EG, Chang Y, Rigotti NA. Other tobacco product and electronic cigarette use among homeless cigarette smokers. *Addictive Behaviors* 2016;**60**: 124–30. [PUBMED: PMC4898780]

Baggett 2016a

Baggett TP, Campbell EG, Chang Y, Magid LM, Rigotti NA. Posttraumatic stress symptoms and their association with smoking outcome expectancies among homeless smokers in Boston. *Nicotine & Tobacco Research* 2016;**18**(6):1526–32. [PUBMED: PMC4906262]

Baggett 2017

Baggett TP, Chang Y, Yaqubi A, McGlave C, Higgins ST, Rigotti NA. Financial incentives for smoking abstinence in homeless smokers: a pilot randomised controlled trial. *Nicotine & Tobacco Research* 2018;**20**(12):1442–50.

Baggett 2018

Baggett TP, Yaqubi A, Berkowitz SA, Kalkhoran SM, McGlave C, Chang Y, et al. Subsistence difficulties

- are associated with more barriers to quitting and worse abstinence outcomes among homeless smokers: evidence from two studies in Boston, Massachusetts. *BMC Public Health* 2018;**18**:463. [PUBMED: PMC5891993]
- Businelle 2014**
Businelle MS, Ma P, Kendzor DE, Reitzel LR, Chen M, Lam CY, et al. Predicting quit attempts among homeless smokers seeking cessation treatment: an ecological momentary assessment study. *Nicotine & Tobacco Research* 2014;**16**(10): 1371–8. [PUBMED: PMID: 24893602]
- Businelle 2014b**
Businelle MS, Kendzor DE, Kesh A, Cuate EL, Poonawalla IB, Reitzel LR, et al. Small financial incentives increase smoking cessation in homeless smokers: a pilot study. *Addictive Behaviors* 2014;**39**(3):717–20.
- Cahill 2013**
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database of Systematic Reviews* 2013, Issue 5. DOI: 10.1002/14651858.CD009329.pub2
- Carpenter 2011**
Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. *Archives of Internal Medicine* 2011;**171**(21):1901–7.
- Carpenter 2015**
Carpenter VL, Hertzberg JS, Kirby AC, Calboun PS, Moore SD, Dennis MF, et al. Multicomponent smoking cessation treatment including mobile contingency management in homeless veterans. *Journal of Clinical Psychiatry* 2015;**76**(7): 959–64.
- Catley 2016**
Catley D, Goggin K, Harris KJ, Richter KP, Williams K, Patten C, et al. A randomized trial of motivational interviewing cessation induction among smokers with low desire to quit. *American Journal of Preventive Medicine* 2016;**50**(5):573–83.
- Chen 2016**
Chen JS, Nguyen AH, Malesker MA, Morrow LE. High-risk smoking behaviors and barriers to smoking cessation among homeless individuals. *Respiratory Care* 2016;**61**(5): 640–5. [PUBMED: PMID: 26860400]
- Connor 2002**
Reed VA, Schifferdecker KE, Rezaee ME, O'Connor S, Larson RJ. Smoking cessation in a homeless population: there is a will, but is there a way?. *Journal of General Internal Medicine* 2002;**17**(5):369–72. [PUBMED: PMID: 12047734]
- Council to Homeless Persons 2018**
Council to Homeless Persons. No room to breathe; why severe overcrowding is a form of homelessness. 2018. <https://chp.org.au/no-room-to-breathe-why-severe-overcrowding-is-a-form-of-homelessness/> (accessed 31 July 2019).
- Culhane 2013**
Culhane DP, Metraux S, Byrne T, Stino M, Bainbridge J. The age structure of contemporary homelessness: evidence and implications for public policy. *Analysis of Social Issues and Public Policy* 2013;**13**(1):228–44.
- Fazel 2008**
Fazel S, Khosla V, Doll H, Geddes J. The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis. *PLoS Medicine* 2008;**5**:e225.
- Fazel 2014**
Fazel S, Geddes JR, Kushel M. The health consequences of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations. *Lancet* 2014;**384**(9953):1529–40.
- Garner 2013**
Garner L, Ratschen E. Tobacco smoking, associated risk behaviours, and experience with quitting: a qualitative study with homeless smokers addicted to drugs and alcohol. *BMC Public Health* 2013;**13**:951. [PUBMED: PMC3853113]
- Goldade 2011**
Goldade K, Whemboula G, Thomas J, Eischen S, Guo H, Connett J, et al. Designing a smoking cessation intervention for the unique needs of homeless persons: a community-based randomized clinical trial. *Clinical Trials* 2011;**8**(6): 744–54. [PUBMED: PMC4729365]
- Higgins 2011**
Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
- Hwang 2009**
Hwang SW, Wilkins R, Tjepkema M, O'Campo PJ, Dunn JR. Mortality among resident of shelters, rooming houses, and hotels in Canada: 11-year follow-up study. *BMJ* 2009;**339**:b4036.
- Jamal 2015**
Jamal A, Homa DM, O'Conner E, Babb SD, Caraballo RS, Singh T, et al. Current cigarette smoking among adults - United States, 2005-2014. *Morbidity and Mortality Weekly Report* 2015;**64**:1233–40.
- Lancaster 2017**
Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. *Cochrane Database of Systematic Reviews* 2017, Issue 3. DOI: 10.1002/14651858.CD001292.pub3
- McInnes 2013**
McInnes DK, Li AE, Hogan TP. Opportunities for engaging low-income, vulnerable populations in health care: a systematic review of homeless persons' access to and use of information technologies. *American Journal of Public Health* 2013;**103**(Suppl 2):e11–24. [PUBMED: PMC3969124]
- Neisler 2018**
Neisler J, Reitzel LR, Garey L, Kendzor DE, Hebert ET, Vijayaraghavan M, et al. Concurrent nicotine and tobacco

- product use among homeless smokers and associations with cigarette dependence and other factors related to quitting. *Drug & Alcohol Dependence* 2018;**185**:133–40.
- Nguyen 2015**
 Nguyen MA, Reitzel LR, Kendzor DE, Businelle MS. Perceived cessation treatment effectiveness, medication preferences, and barriers to quitting among light and moderate/heavy homeless smokers. *Drug & Alcohol Dependence* 2015;**153**:341–5. [PUBMED: PMID: 26072221]
- Notley 2019**
 Notley C, Gentry S, Livingstone-Banks J, Bauld L, Perera R, Hartmann-Boyce J. Incentives for smoking cessation. *Cochrane Database of Systematic Reviews* 2019, Issue 7. DOI: 10.1002/14651858.CD004307.pub6
- Ojo-Fati 2015**
 Ojo-Fati O, John F, Thomas J, Joseph AM, Raymond NC, Cooney NL, et al. Integrating smoking cessation and alcohol use treatment in homeless populations: study protocol for a randomized controlled trial. *Trials* 2015;**16**:385.
- Okuyemi 2006**
 Okuyemi KS, Caldwell AR, Thomas JL, Born W, Richter KP, Nollen N, et al. Homelessness and smoking cessation: insights from focus groups. *Nicotine & Tobacco Research* 2006;**8**(2):287–96.
- Okuyemi 2013**
 Okuyemi KS, Goldade K, Whembolua GL, Thomas JL, Eischen S, Sewali B, et al. Motivational interviewing to enhance nicotine patch treatment for smoking cessation among homeless smokers: a randomised controlled trial. *Addiction* 2013;**108**(6):1136–44.
- Okuyemi 2006b**
 Okuyemi KS, Thomas JL, Hall S, Nollen NL, Richter KP, Jeffries SK, et al. Smoking cessation in homeless populations: a pilot clinical trial. *Nicotine & Tobacco Research* 2006;**8**(5):689–99.
- Rash 2018**
 Rash C, Petry N, Alessi S. A randomized trial of contingency management for smoking cessation for the homeless. *Psychology of Addictive Behaviors* 2018;**32**(2):141–8.
- Reitzel 2011**
 Reitzel LR, Cromley EK, Li Y, Cao Y, Dela Mater R, Mazas CA, et al. The effect of tobacco outlet density and proximity on smoking cessation. *American Journal of Public Health* 2011;**101**(2):315–20. [PUBMED: PMID: 21164089]
- Reitzel 2014**
 Reitzel LR, Nguyen N, Eischen S, Thomas J, Okuyemi KS. Is smoking cessation associated with worse comorbid substance use outcome among homeless adults?. *Addiction* 2014;**109**(12):2098–104. [PUBMED: PMID:25041459]
- Schroeder 2009**
 Schroeder SA, Morris CD. Confronting a neglected epidemic: tobacco cessation for persons with mental illnesses and substance abuse problems. *Annual Review of Public Health* 2009;**31**:297–314.
- Shadel 2014**
 Shadel WG, Tucker JS, Mullins L, Staplefoot L. Providing smoking cessation programs to homeless youth: the perspective of service providers. *Journal of Substance Abuse Treatment* 2014;**47**(4):251–7.
- Stead 2016**
 Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. *Cochrane Database of Systematic Reviews* 2016, Issue 3. DOI: 10.1002/14651858.CD008286.pub3
- Vijayaraghavan 2014**
 Vijayaraghavan M, Penko J, Vittinghoff E, Bangsberg DR, Miaskowski C, Kushel MB. Smoking behaviours in a community-based cohort of HIV-infected indigent adults. *AIDS and Behavior* 2014;**18**(3):535–43. [PUBMED: PMID: 23918243]
- Vijayaraghavan 2015**
 Vijayaraghavan M, Pierce JP. Interest in smoking cessation related to a smoke-free policy among homeless adults. *Journal of Community Health* 2015;**40**(4):686–91. [PUBMED: PMID: 25559109]
- Vijayaraghavan 2016**
 Vijayaraghavan M, Tieu L, Ponath C, Guzman D, Kushel M. Tobacco cessation behaviors among older homeless adults: results from the HOPE HOME study. *Nicotine & Tobacco Research* 2016;**18**(8):1733–9. [PUBMED: PMID: 26920648]
- Vijayaraghavan 2016b**
 Vijayaraghavan M, Hurst S, Pierce P. Implementing tobacco control programs in homeless shelters: a mixed-methods study. *Health Promotion Practice* 2016;**17**(4):501–11. [PUBMED: PMID: 26678988]
- Vijayaraghavan 2017**
 Vijayaraghavan M, Hurst S, Pierce JP. A qualitative examination of smoke-free policies and electronic cigarettes among sheltered homeless adults. *American Journal of Health Promotion* 2017;**31**(3):243–50. [PUBMED: PMID: 26559719]
- Vijayaraghavan 2018**
 Vijayaraghavan M, Olsen P, Weeks J, McKelvey L, Ponath C, Kushel M. Older African American homeless-experienced smokers' attitudes toward tobacco control policies - results from the HOPE HOME study. *American Journal of Health Promotion* 2018;**32**(2):381–91. [PUBMED: PMC5858921]

* Indicates the major publication for the study

APPENDICES

Appendix I. MEDLINE search strategy

1. (un-housed* OR homeless* OR “unstably housed” OR runaway OR “homeless persons”[mesh] OR housing instability)
2. ((smoking cessation.mp. OR exp Smoking Cessation/) OR “Tobacco-Use-Cessation”/ OR “Tobacco-Use-Disorder”/ OR Tobacco-Smokeless/ OR exp Tobacco-/ OR ((quit\$ or stop\$ or ceas\$ or giv\$) adj5 smoking).ti,ab.)) OR exp Smoking/)
3. ((randomised controlled trial[pt]) OR (controlled clinical trial[pt]) OR (clinical trial[pt])) OR ((pragmatic clinical trial)) NOT (animals[mh]))
4. 1 AND 2 AND 3

CONTRIBUTIONS OF AUTHORS

The protocol was conceived and prepared by Maya Vijayaraghavan, Holly Elser, and Dorie Apollonio.

DECLARATIONS OF INTEREST

Maya Vijayaraghavan has no conflicts of interest to report. MV has one pending grant application on the topic of smoke-free policies in permanent supportive housing for formerly homeless populations.

Holly Elser has no conflicts of interest to report.

Dorie Apollonio has no conflicts of interest to report.

SOURCES OF SUPPORT

Internal sources

- Univeristy of California, San Francisco, San Francisco Cancer Initiative, USA.

External sources

- Tobacco Related Disease Reseach Program, USA.
- Grant